Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2016

View Archived Issues

EIB and Transgene enter a financing agreement

Adicet Bio closes Series A financing and acquires Applied Immune Technologies

Epic Sciences and Avera Medical collaborate in personalized cancer medicine trials

RSV Corporation ends RSV collaboration with Mymetics

Shionogi and Nissan Chemical enter strategic antifungal research collaboration agreement

Elotuzumab receives positive CHMP opinion for the treatment of multiple myeloma

VARI-SU2C Epigenetics Dream Team advances trial for metastatic colorectal cancer

Synthetic anion carrier shows activity without toxicity

AbbVie starts enrollment in phase III clinical program for elagolix in uterine fibroids

First patients dosed in phase I trial of ARQ-092 in Proteus syndrome

GenArraytion introduces first commercially available Zika virus test

Cancer drug exhibits promising preclinical results in a DMD model

Allergan enters into a global agreement with AstraZeneca to develop and commercialize ATM-AVI

Celgene reviews activities of fourth quarter 2015

Sareum applies for permission to start clinical trials of Chk1 inhibitor CCT-245737

Amgen reports milestones from fourth quarter 2015

EMA accepts cabozantinib MAA for review

BeiGene reports inhibitors of EGFR T790M mutant

Synergy Pharmaceuticals submits NDA for plecanatide

Pfizer reports muscarinic M1 PAMs

Merck Patent and Cancer Research Technology develop CDK8/19 inhibitors

EMA committee backs approval of Uptravi for PAH

Advenchen Laboratories presents PI3K/mTOR inhibitors

EMA committee recommends approval of Coagadex to treat FX deficiency

FDA gives breakthrough therapy designation to Allergan's rapastinel

Merck & Co. reports ROMK inhibitors

Spectrum Pharmaceuticals begins registrational trial of eflapegrastim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...